Logo
x

Search

Subscribe Now

novartis

Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer

Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer

  • December 11, 2024
Novartis’ Kisqali (Ribociclib) Secures EC’s Approval as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer

Novartis’ Kisqali (Ribociclib) Secures EC’s Approval as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer

  • November 27, 2024
Novartis Reports the Acquisition of Kate Therapeutics for ~$1.1B

Novartis Reports the Acquisition of Kate Therapeutics for ~$1.1B

  • November 22, 2024
The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

  • October 30, 2024
Monte Rosa Therapeutics and Novartis Collaborate to Advance VAV1-directed Molecular Glue Degraders (MGD)

Monte Rosa Therapeutics and Novartis Collaborate to Advance VAV1-directed Molecular Glue Degraders (MGD)

  • October 29, 2024
Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)

Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)

  • October 28, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.